Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.83 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.83 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.83 |
| ▸ | MEN1 | O00255 | 1/20 | 0.83 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.83 |
| ▸ | MAPT | P10636 | 1/20 | 0.76 |
| ▸ | ENPP2 | Q13822 | 6/20 | 0.76 |
| ▸ | LPAR1 | Q92633 | 6/20 | 0.76 |
| ▸ | LPAR4 | Q99677 | 3/20 | 0.76 |
| ▸ | LPAR5 | Q9H1C0 | 3/20 | 0.76 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.76 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.76 |
| ▸ | LPAR6 | P43657 | 2/20 | 0.76 |
| ▸ | DGKA | P23743 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.65 |
| ▸ | CES2 | O00748 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7576639 | 1.00 | LMNA (0.83) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL9463924 | 1.00 | LMNA (0.83) | LMNAKDM4EDUSP3MEN1KMT2A | |
| 1,3-Dipalmitin SCHEMBL471830 | 1.00 | LMNA (0.83) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL9463581 | 1.00 | LMNA (0.83) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL21660226 | 1.00 | LMNA (0.83) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL11787098 | 1.00 | LMNA (0.83) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL19944297 | 1.00 | LMNA (0.83) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL9465207 | 1.00 | LMNA (0.83) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL17584914 | 1.00 | LMNA (0.83) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL17129723 | 1.00 | LMNA (0.83) | LMNAKDM4EDUSP3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709710-A1 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | Arcturus Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20240391870-A1 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | ARCTURUS THERAPEUTICS, INC. | 2024-11-28 | — | — | US | disclosed |
| WO-2024233750-A1 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | ARCTURUS THERAPEUTICS, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| EP-4430026-A1 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | Arcturus Therapeutics, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| US-20230295081-A1 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | ARCTURUS THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295081-A1 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | ARCTURUS THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295081-A1 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | ARCTURUS THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-11744818-B2 | Application of trans-1,3-dilinolein in the preparation of medicaments for treating gastric cancer, stomachic tonic, health products and foods | LANZHOU UNIVERSITY (CN) | 2023-09-05 | — | — | US | disclosed |
| US-11744818-B2 | Application of trans-1,3-dilinolein in the preparation of medicaments for treating gastric cancer, stomachic tonic, health products and foods | LANZHOU UNIVERSITY (CN) | 2023-09-05 | — | — | US | disclosed |
| WO-2023086514-A1 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | ARCTURUS THERAPEUTICS, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| US-8487001-B2 | Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors | PROMETIC BIOSCIENCES INC. (CA) | 2013-07-16 | — | — | US | disclosed |
| US-20100279959-A1 | Medium-Chain Length Fatty Acids, Glycerides and Analogues as Neutrophil Survival and Activation Factors | PROMETIC PHARMA SMT LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
| US-20100279959-A1 | Medium-Chain Length Fatty Acids, Glycerides and Analogues as Neutrophil Survival and Activation Factors | PROMETIC PHARMA SMT LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
| US-7745488-B2 | Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors | PROMETIC BIOSCIENCES, INC. (CA) | 2010-06-29 | — | — | US | disclosed |
| US-7745488-B2 | Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors | PROMETIC BIOSCIENCES, INC. (CA) | 2010-06-29 | — | — | US | disclosed |
| WO-1996006823-A1 | DICARBOXYLIC ACID ESTER DERIVATIVES WITH A DIACYLOXYPROPYL RESIDUE | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1996-03-07 | — | — | WO | disclosed |
| US-5225590-A | Alkoxy methyl ether and alkoxy methyl ester derivatives | SYNTEX (U.S.A.) INC. (US) | 1993-07-06 | — | — | US | disclosed |
| EP-0187297-B1 | ALKOXY METHYL ETHER AND ALKOXY METHYL ESTER DERIVATIVES | SYNTEX (U.S.A.) INC. (US) | 1991-08-21 | — | — | EP | disclosed |
| EP-0187297-A2 | Alkoxy methyl ether and alkoxy methyl ester derivatives | SYNTEX (U.S.A.) INC. (US) | 1986-07-16 | — | — | EP | disclosed |
| US-4477447-A | ANTIBIOTIC, BACTERICIDE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240391870-A1 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | NSUN3, POLRMT, NPC1L1 | LMNA 1041/4885KDM4E 4135/4885DUSP3 4735/4885 |
| US-20230295081-A1 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | NSUN3, POLRMT, NPC1L1 | LMNA 1041/4885KDM4E 4135/4885DUSP3 4735/4885 |
| US-11744818-B2 | Application of trans-1,3-dilinolein in the preparation of medicaments for treating gastric cancer, stomachic tonic, health products and foods | HYOU1, TGOLN2, DSG1 | LMNA 661/4885KDM4E 3635/4885DUSP3 1226/4885 |
| US-20100279959-A1 | Medium-Chain Length Fatty Acids, Glycerides and Analogues as Neutrophil Survival and Activation Factors | MYD88, CSF3R, MCTS1 | LMNA 3255/4885KDM4E 4806/4885DUSP3 2204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.